CRISM Therapeutics Corporation
CRTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | -£0 | -£0 | -£0 |
| Revenue | £0 | – | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£0 | – | -£0 | £0 |
| % Margin | – | – | – | – |
| EBITDA | -£0 | – | £0 | -£0 |
| % Margin | – | – | – | – |
| Net Income | -£0 | – | -£0 | -£0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.038 | – | -0.002 | 0.23 |
| % Growth | – | – | -100.9% | – |
| Operating Cash Flow | -£0 | £0 | -£0 | -£0 |
| Capital Expenditures | £0 | £0 | -£0 | £0 |
| Free Cash Flow | -£0 | £0 | -£0 | -£0 |